GlassScriptPhysician profile
Bruce A Beesley
NPI 1215986765
$2,445.77
in general payments reported to CMS, 2019-2025
14 companies · $287 in 2025
The $287 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,056 · 2021: $65.46 · 2022: $162 · 2023: $325 · 2024: $550 · 2025: $287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,161.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $980.57 | 2019 | |
| Abbvie INC. | $625.63 | 2021-2024 | Qulipta, Ubrelvy, Botox |
| Pfizer INC. | $186.38 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $134.33 | 2024 | Ultomiris |
| Eisai INC. | $122.88 | 2023 | |
| Novartis Pharmaceuticals Corporation | $99.64 | 2019-2023 | |
| Supernus Pharmaceuticals, INC. | $69.20 | 2025 | Qelbree |
| Lundbeck LLC | $51.37 | 2025 | Vyepti |
| Celgene Corporation | $50.12 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $36.34 | 2025 | |
| Mdd US Operations, LLC | $28.94 | 2025 | Gocovri |
| Biogen, INC. | $26.45 | 2024 | Vumerity, Tysabri |
| Amgen INC. | $18.27 | 2025 | Uplizna |
| Biohaven Pharmaceuticals, INC. | $15.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Beesley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.